Clinical Trial Update: Pharmacogenomic & Phase II Study of Gemcitabine and Pemetrexed in Non-Small-Cell Lung Cancer. [Phase 2]

View source ↗

Summary

A Phase II pharmacogenomic study evaluating the combination of gemcitabine and pemetrexed in non-small cell lung cancer, with results posted after completion.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• Alimta (pemetrexed)
• Gemzar (gemcitabine)

Snippet

Sponsor: H. Lee Moffitt Cancer Center and Research Institute | Conditions: Lung Cancer | Phase 2 | Status: COMPLETED | Results posted: 2011-01-12